Pharmacokinetic and anti-tumor studies with the radiosensitizer misonidazole in dogs with spontaneous fibrosarcomas.
Nine dogs with spontaneous oral fibrosarcomas were given the radiosensitizer misonidazole (Ro-07-0582) In combination with orthovoltage radiotherapy. Although there appeared to be a trend toward greater disease-free survival of these animals as compared with a group of 13 dogs with similar tumors treated by orthovoltage x-rays alone, on analysis there was no significant difference. The plasma half-life and the volume of distribution of misonidazole were determined as 4.95 hours and 15.1 L/m2, respectively. In 3 dogs with evidence of misonidazole toxicosis, plasma concentrations at 4 hours after the dose exceeded 85 microgram/ml, and the areas under the concentration vs time curve for this first 10 hours were greater than 850 microgram.hr/ml.
D000818:Animals; D004283:Dog Diseases / Q000532:radiotherapy*; D004285:Dogs; D005354:Fibrosarcoma / Q000532:radiotherapy / Q000662:veterinary*; D008339:Mandibular Neoplasms / Q000532:radiotherapy / Q000662:veterinary*; D008441:Maxillary Neoplasms / Q000532:radiotherapy / Q000662:veterinary*; D008920:Misonidazole / Q000097:blood / Q000627:therapeutic use* / Q000633:toxicity; D009062:Mouth Neoplasms / Q000532:radiotherapy / Q000662:veterinary*; D009593:Nitroimidazoles / Q000627:therapeutic use*; D010160:Palate, Soft
D009593:Nitroimidazoles; D008920:Misonidazole